Menu ×

HEALTHCARE & PHARMACEUTICAL

Cholinesterase Inhibitors Market Segmentation By Chemical (Rivastigmine, Donepezil, Galantamine and Tacrine); By Indication (Alzheimer’s Disease, Myasthenia Gravis, Parkinson’s Disease, Dementia, Schizophrenia and Others); By Route of Administration (Oral and Transdermal) – Global Demand Analysis & Opportunity Outlook 2028

  • Text Size:

Extensive insights into the Growth of Cholinesterase Inhibitors Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More
IN THE NEWS
  • On July 11, 2019, Novartis, Amgen and Banner Alzheimer’s Institute announced that they would discontinue any further investigation of the BACE1 inhibitor CNP520 in their Phase II/III trials in their Alzheimer’s Prevention Initiative Generation Program as the potential benefits in the studies were not found to outweigh the risks. This can be estimated to result in more research and focus on cholinesterase inhibitors.

Introduction to Cholinesterase Inhibitors

Cholinesterase inhibitors, also known as acetylcholinesterase inhibitors, are chemicals used for the blockage of normal decomposition of acetylcholine. Acetylcholine is another chemical that acts as the main neurotransmitter for both the central as well as the peripheral nervous system. This neurotransmitter is broken down with the help of an enzyme called cholinesterase, and the action of this enzyme is blocked by cholinesterase inhibitors, thereby preventing the breakdown of acetylcholine. This allows more acetylcholine to reach the brain and help with increasing cognition. Cholinesterase inhibitors are primarily used for reducing the symptoms related with disorders such as dementia and Alzheimer’s disease among other neural disorders.

Market Size and Forecast

The cholinesterase inhibitors market is anticipated to record a significantly high CAGR over the forecast period, i.e., 2020-2028. The market is segmented by chemical, by indication, by route of administration and by region, out of which, the chemical segment is further segmented into rivastigmine, donepezil, galantamine and tacrine. Out of these, all cholinesterase inhibitors have been approved by the U.S. Food and Drug Administration (FDA), however, only three of these, i.e., rivastigmine, donepezil and galantamine are sold in the United States. The sale of tacrine has been discontinued.

Based on route of administration, the market is segmented into oral and transdermal. The oral route of administration is anticipated to hold the largest share in the cholinesterase inhibitors market on account of tablets and capsules being the most common dosage form. Based on indication, the market is segmented into Alzheimer’s disease, myasthenia gravis, Parkinson’s disease, dementia, schizophrenia and others. The Alzheimer’s disease segment is predicted to grow at the highest rate as a result of rising cases of the disease which increase the demand for cholinesterase inhibitors in the market. As per the 2019 statistics by the Alzheimer’s Association, Alzheimer’s disease is the most common cause of dementia and accounts for an estimated 60% to 80% of all cases. CLICK TO DOWNLOAD SAMPLE REPORT

Cholinesterase Inhibitors Market

Growth Drivers

Growing Cases of Disorders Associated with Dementia to Drive the Market Growth

According to the Alzheimer’s Association, Alzheimer’s disease is the 6th leading cause of death in the United States, with around 5 million people living with the disorder. Further, it estimates that deaths from heart diseases have decreased by 7.8% between 2000 and 2018. On the other hand, deaths from Alzheimer’s disease have increased by 146% in the country. The growing number of deaths as a result of this disorder is anticipated to increase the demand for drugs that treat the disease or relieve the symptoms of the disorder. On account of this, the market is predicted to grow in the coming years.

Generation of High Revenue Through Approved Drugs to Provide Increased Business Opportunities

The approved cholinesterase inhibitors are available in the market under several brand names which are manufactured and marketed by various leading pharmaceutical companies. The high demand for these drugs is estimated to result in the generation of high revenue, which is further predicted to increase business opportunities in the market.

Restraints

Limited Availability of Medicines to Restrict the Market Growth

Cholinesterase inhibitors can only be used for reducing the symptoms of dementia and other conditions and not for their cure. This is predicted to limit the demand for these inhibitors in the market in the next few years.

Market Segmentation

Our in-depth analysis of the cholinesterase inhibitors market includes the following segments:

By Chemical

  • Rivastigmine
  • Donepezil
  • Galantamine
  • Tacrine

By Indication

  • Alzheimer’s Disease
  • Myasthenia Gravis
  • Parkinson’s Disease
  • Dementia
  • Schizophrenia
  • Others

By Route of Administration

  • Oral
  • Transdermal

By Region

On the basis of regional analysis, the cholinesterase inhibitors market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.

The market for cholinesterase inhibitors in North America is estimated to hold the largest share in the market which can be accounted for presence of major leading key players in the industry in this region, especially in the United States. The market in Asia Pacific is predicted to witness highest growth rate over the forecast period as a result of booming demand for medicines for the treatment of dementia and Alzheimer’s disease.

The cholinesterase inhibitors market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC,  Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Top Featured Companies Dominating the Market

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2020 Research Nester. All Rights Reserved